Merck Presents Early-Phase Bladder and Kidney Cancer Data at 2026 ASCO GU Symposium
Merck presented new clinical data on bladder and kidney cancer therapies at the 2026 ASCO GU Cancers Symposium, showing durable responses and manageable safety profiles in early-phase trials. The findings reinforce advancement plans for these candidates into larger registrational studies.
1. ASCO GU Symposium Presentation
On February 12 at the 2026 ASCO GU Cancers Symposium, Merck detailed outcomes from early-phase trials evaluating its investigational immunotherapy regimens for bladder and kidney cancers, highlighting durable disease control and an acceptable safety profile.
2. Development and Next Steps
Merck plans to initiate larger registrational trials later this year to confirm efficacy and safety signals, aiming to expand its oncology portfolio and pursue regulatory submissions based on the new data.